S. Kollack-Walker

发表

Social Stress in Hamsters: Defeat Activates Specific Neurocircuits within the Brain

H. Akil, S. Watson, S J Watson, 1997, The Journal of Neuroscience.

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy

J. Csernansky, R. Keefe, I. Lipkovich, 2009, BMC psychiatry.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

M. Mintun, A. Fleisher, E. Siemers, 2017, Alzheimer's & Dementia.

Differential rate of weight gain present among patients treated with olanazpine

B. Kinon, S. Kollack-Walker, M. Rotelli, 2003, Schizophrenia Research.

Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders

B. Kinon, S. Kollack-Walker, Saeed Ahmed, 2005, Journal of clinical psychopharmacology.

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia

R. Conley, S. Ruberg, J. Kane, 2011, BMC psychiatry.

Central Stress Neurocircuits

H. Akil, S. Kollack-Walker, H. Day, 2007 .

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

T. Hardy, I. Lipkovich, A. Heinloth, 2008, Therapeutics and clinical risk management.

Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.

B. Kinon, S. Kollack-Walker, Hong Liu, 2003, The international journal of neuropsychopharmacology.

Mating‐Induced c‐fos Expression Patterns Complement and Supplement Observations after Lesions in the Male Syrian Hamster Brain a

S. Newman, S. Kollack-Walker, D. Parfitt, 1997, Annals of the New York Academy of Sciences.

Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.

J. Czekalla, C. Beasley, S. Kollack-Walker, 2001, The Journal of clinical psychiatry.

Social defeat alters the acquisition of cocaine self-administration in rats: role of individual differences in cocaine-taking behavior

H. Akil, S. Watson, M. Kabbaj, 2001, Psychopharmacology.

Mating and agonistic behavior produce different patterns of Fos immunolabeling in the male Syrian hamster brain

S. Newman, S. Kollack-Walker, 1995, Neuroscience.

Expression of c-fos gene activation during rough and tumble play in juvenile rats

Nakia S. Gordon, J. Panksepp, H. Akil, 2002, Brain Research Bulletin.

Optimal thresholds of early response to atypical antipsychotics: Application of signal detection methods

S. Ruberg, H. Ascher-Svanum, B. Kinon, 2009, Schizophrenia Research.

Randomized, Double-blind 6-Month Comparison of Olanzapine and Quetiapine in Patients With Schizophrenia or Schizoaffective Disorder With Prominent Negative Symptoms and Poor Functioning

H. Ascher-Svanum, B. Kinon, D. Noordsy, 2006, Journal of clinical psychopharmacology.

Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods

D. Jeste, B. Kinon, H. Liu-Seifert, 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease

E. Siemers, P. Aisen, M. Case, 2017, Alzheimer's & Dementia.

Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.

B. Kinon, H. Liu-Seifert, S. Kollack-Walker, 2012, Journal of clinical psychopharmacology.

Mating-induced expression of c-fos in the male Syrian hamster brain: role of experience, pheromones, and ejaculations.

S. Newman, S. Kollack-Walker, 1997, Journal of neurobiology.

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial

J. Johnston, D. Naber, P. Succop, 2011, BMC psychiatry.

The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly.

A. Fleisher, Collin Y. Liu, S. Kollack-Walker, 2017, Neurologic clinics.

OLANZAPINE VERSUS ARIPIPRAZOLE FOR THE TREATMENT OF AGITATION IN ACUTELY ILL PATIENTS WITH SCHIZOPHRENIA

B. Kinon, S. Kollack-Walker, Lei Chen, 2008, Schizophrenia Research.

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.

P. Weiden, H. Ascher-Svanum, B. Kinon, 2014, Clinical schizophrenia & related psychoses.

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

B. Kinon, S. Kollack-Walker, O. Osuntokun, 2011, Journal of clinical psychopharmacology.

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis

J. Lieberman, R. Conley, M. Case, 2011, Psychiatry Research.

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

J. Kane, H. Ascher-Svanum, B. Kinon, 2008, Schizophrenia Research.

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

S. Kapur, J. Kane, H. Ascher-Svanum, 2010, Neuropsychopharmacology.

Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia

S. Kapur, D. Naber, H. Ascher-Svanum, 2010, Schizophrenia Research.

Incidence of Tardive Dyskinesia in Older Adult Patients Treated With Olanzapine or Conventional Antipsychotics

D. Jeste, M. Case, B. Kinon, 2015, Journal of geriatric psychiatry and neurology.

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

R. Conley, S. Kollack-Walker, V. P. Hoffmann, 2010, BMC psychiatry.

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy

J. Kane, H. Ascher-Svanum, B. Kinon, 2011, ClinicoEconomics and outcomes research : CEOR.

Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials

S. Kapur, M. Case, H. Ascher-Svanum, 2011, Schizophrenia Research.

The heterogeneity of antipsychotic response in the treatment of schizophrenia

S. Kapur, R. Conley, J. Kane, 2010, Schizophrenia Research.

Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.

J. Csernansky, J. Peuskens, I. Lipkovich, 2007, Journal of psychiatric research.

Principles of psychoneuroendocrinology.

S. Watson, S. Kollack-Walker, S. Campeau, 1998, The Psychiatric clinics of North America.

Early Onset of Antipsychotic Action in Schizophrenia: Evaluating the Possibility of Shorter Acute Efficacy Trials

S. Kapur, H. Ascher-Svanum, B. Kinon, 2010, Journal of clinical psychopharmacology.

PMH51 THE COST-EFFECTIVENESS OF EARLY RESPONDERS VERSUS EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTIC THERAPY

J. Kane, H. Ascher-Svanum, B. Kinon, 2010 .

Predicting a ‘Combined Treatment Outcome’ in Chronic Schizophrenia: The Role of Demographics, Symptomatology, Functioning and Subjective Well-being

S. Kapur, J. Chen, J. Kane, 2013, Pharmacopsychiatry.

S.05.02 Early response as a response predictor: use of individual variability in clinical trials

J. Kane, H. Ascher-Svanum, B. Kinon, 2009, European Neuropsychopharmacology.

Comments on "Optimizing early prediction for antipsychotic response in schizophrenia" by Chang et al.

I. Lipkovich, S. Kollack-Walker, Lei Chen, 2009, Journal of Clinical Psychopharmacology.

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

B. Kinon, Simin K. Baygani, S. Kollack-Walker, 2013, BMC Psychiatry.

Differential Expression of c‐fos mRNA Within Neurocircuits of Male Hamsters Exposed to Acute or Chronic Defeat

Akil, H. Akil, C. Don, 1999, Journal of neuroendocrinology.

Clinicoeconomics and Outcomes Research Dovepress Cost-effectiveness of Early Responders versus Early Nonresponders to Atypical Antipsychotic Therapy

J. Kane, H. Ascher-Svanum, B. Kinon, 2022 .

Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.

B. Kinon, H. Liu-Seifert, S. Kollack-Walker, 2012, Journal of clinical psychopharmacology.

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy

J. Csernansky, R. Keefe, I. Lipkovich, 2009, BMC psychiatry.

Defining “good” and “poor” outcomes in patients with schizophrenia or schizoaffective disorder: A multidimensional data-driven approach

J. Csernansky, J. Peuskens, I. Lipkovich, 2009, Psychiatry Research.